Table of contents


On 31 October 2006, orphan designation (EU/3/06/419) was granted by the European Commission to MediGene AG, Germany, for paclitaxel (liposomal) for the treatment of pancreatic cancer.

The sponsorship was transferred to SynCore Biotechnology Europe GmbH, Germany, in June 2016.

Key facts

Active substance
Paclitaxel (liposomal)
Disease / condition
Treatment of pancreatic cancer
Date of decision
Orphan decision number

Sponsor's contact details

SynCore Biotechnology Europe GmbH
c/o Hogan Lovells International LLP
Karl-Scharnagl-Ring 5
80539 Munich
Tel. +49 89 29 01 20
Fax +49 89 29 01 22 22

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating